Stéphane Culine

8.8k total citations · 2 hit papers
163 papers, 4.6k citations indexed

About

Stéphane Culine is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Stéphane Culine has authored 163 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 85 papers in Pulmonary and Respiratory Medicine, 71 papers in Oncology and 67 papers in Surgery. Recurrent topics in Stéphane Culine's work include Bladder and Urothelial Cancer Treatments (49 papers), Prostate Cancer Treatment and Research (44 papers) and Urinary and Genital Oncology Studies (26 papers). Stéphane Culine is often cited by papers focused on Bladder and Urothelial Cancer Treatments (49 papers), Prostate Cancer Treatment and Research (44 papers) and Urinary and Genital Oncology Studies (26 papers). Stéphane Culine collaborates with scholars based in France, United States and Spain. Stéphane Culine's co-authors include Christine Théodore, Joaquim Bellmunt, Hans von der Maase, Yacine Salhi, Frédéric Rolland, Eric Winquist, F. Iborra, Jean‐Pierre Droz, Stéphane Oudard and Toni K. Choueiri and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Molecular and Cellular Biology.

In The Last Decade

Stéphane Culine

154 papers receiving 4.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

2009 543 citations Joaquim Bellmunt, Christine Théodore et al. Journal of Clinical Oncology profile →
Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, Florence Joly et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stéphane Culine France	34	2.0k	1.7k	1.6k	1.4k	1.0k	163	4.6k
Richard Cathomas Switzerland	28	1.3k 0.7×	2.0k 1.1×	1.5k 0.9×	1.1k 0.8×	525 0.5×	149	4.0k
Begoña Mellado Spain	36	2.2k 1.1×	947 0.5×	1.9k 1.2×	2.0k 1.5×	1.1k 1.1×	180	4.7k
Jan B. Vermorken Belgium	23	2.1k 1.1×	1.4k 0.8×	3.1k 1.9×	1.3k 1.0×	499 0.5×	45	5.6k
Miao‐Zhen Qiu China	38	1.6k 0.8×	1.1k 0.6×	2.5k 1.6×	1.6k 1.2×	1.3k 1.2×	165	4.9k
Ignacio Durán Spain	37	1.4k 0.7×	1.6k 0.9×	2.3k 1.4×	1.5k 1.1×	562 0.6×	206	4.8k
Roberto Iacovelli Italy	34	2.6k 1.3×	712 0.4×	2.1k 1.3×	1.5k 1.1×	1.2k 1.2×	224	4.6k
Jae Kyung Roh South Korea	30	1.8k 0.9×	1.2k 0.7×	4.2k 2.6×	1.1k 0.8×	862 0.8×	156	5.9k
Hendrik‐Tobias Arkenau United Kingdom	34	1.2k 0.6×	818 0.5×	2.3k 1.4×	1.5k 1.1×	769 0.8×	214	4.1k
Bernhard J. Eigl Canada	28	3.2k 1.6×	820 0.5×	1.5k 0.9×	1.7k 1.3×	1.6k 1.5×	135	4.6k
Evan Y. Yu United States	40	3.2k 1.6×	1.6k 0.9×	2.4k 1.5×	1.4k 1.1×	1.2k 1.2×	294	5.9k

Countries citing papers authored by Stéphane Culine

Since Specialization

Citations

This map shows the geographic impact of Stéphane Culine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Culine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Culine more than expected).

Fields of papers citing papers by Stéphane Culine

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Culine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Culine. The network helps show where Stéphane Culine may publish in the future.

Co-authorship network of co-authors of Stéphane Culine

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Culine. A scholar is included among the top collaborators of Stéphane Culine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Culine. Stéphane Culine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gross‐Goupil, Marine, Éric Frison, Guilhem Roubaud, et al.. (2024). GCISAVE: A non-comparative randomized phase II study of combination of gemcitabine cisplatin (GCis) +/- avelumab (A) in 1st line treatment for locally advanced or metastatic urothelial bladder carcinoma (MUBC)—GETUG AFU V07.. Journal of Clinical Oncology. 42(4_suppl). 637–637. 1 indexed citations

Dumont, Clément, et al.. (2023). Short-Course Treatment after Complete Response to Pembrolizumab in Metastatic Urothelial Bladder Cancer: A Case Series. Immunotherapy. 15(10). 729–735.

Culine, Stéphane, Valentin Harter, Clémentine Krucker, et al.. (2023). Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial. Cancers. 15(6). 1742–1742. 6 indexed citations

Colomba, Émeline, Grégoire Marret, Giulia Baciarello, et al.. (2020). Liver tests increase on abiraterone acetate in men with metastatic prostate cancer: Natural history, management and outcome. European Journal of Cancer. 129. 117–122. 11 indexed citations

Dalban, Cécile, Brigitte Laguerre, Sylvain Ladoire, et al.. (2020). 712P Primary tumour response in patients treated with nivolumab for metastatic renal cell carcinoma (mRCC): Results of the GETUG-AFU 26 NIVOREN trial. Annals of Oncology. 31. S560–S561. 1 indexed citations

Dumont, Clément, Jérôme Verine, Floriane Noël, et al.. (2019). CD8+PD-1–ILT2+ T Cells Are an Intratumoral Cytotoxic Population Selectively Inhibited by the Immune-Checkpoint HLA-G. Cancer Immunology Research. 7(10). 1619–1632. 53 indexed citations

Marret, Grégoire, Ludovic Doucet, Christophe Hennequin, Karim Fizazi, & Stéphane Culine. (2018). Abiraterone in metastatic castration-resistant prostate cancer: Efficacy and safety in unselected patients. Cancer Treatment and Research Communications. 17. 37–42. 6 indexed citations

Moktefi, Anissa, Damien Pouessel, Jing Liu, et al.. (2018). Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility. Modern Pathology. 31(8). 1270–1281. 26 indexed citations

Ravaud, Alain, Stéphane Oudard, Marc de Fromont, et al.. (2015). First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG). Annals of Oncology. 26(6). 1123–1128. 121 indexed citations

10.

Bellmunt, Joaquim, Ronan Fougeray, Jacob Rosenberg, et al.. (2013). Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum-based chemotherapy. Annals of Oncology. 24(6). 1466–1472. 115 indexed citations

11.

Fritz, Vanessa, Zohra Benfodda, Geneviève Rodier, et al.. (2010). Abrogation of De novo Lipogenesis by Stearoyl-CoA Desaturase 1 Inhibition Interferes with Oncogenic Signaling and Blocks Prostate Cancer Progression in Mice. Molecular Cancer Therapeutics. 9(6). 1740–1754. 231 indexed citations

12.

Ploussard, Guillaume, Stéphane Terry, Pascale Maillé, et al.. (2010). Class III β-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Research. 70(22). 9253–9264. 121 indexed citations

13.

Joly, Florence, Nadine Houédé, Sabine Noal, et al.. (2009). Do Patients With Advanced Urothelial Carcinoma Benefit From Weekly Paclitaxel Chemotherapy? A GETUG Phase II Study. Clinical Genitourinary Cancer. 7(2). E28–E33. 41 indexed citations

14.

Bastien, Laurence, et al.. (2009). Targeted therapies in metastatic renal cancer in 2009. British Journal of Urology. 103(10). 1334–1342. 13 indexed citations

15.

Patard, Jean‐Jacques, Damien Pouessel, Karim Bensalah, & Stéphane Culine. (2008). Targeted therapy in renal cell carcinoma. World Journal of Urology. 26(2). 135–140. 36 indexed citations

16.

Culine, Stéphane, et al.. (2007). Docetaxel and Cisplatin in Patients With Metastatic Androgen Independent Prostate Cancer and Circulating Neuroendocrine Markers. The Journal of Urology. 178(3). 844–848. 82 indexed citations

17.

Raymond, Éric, Svein Dueland, Michael Lind, et al.. (2005). Pharmacokinetics of a nucleoside analogue CP-4055 in two phase I trials using a daily for 5 days schedule and three intermittent weekly or biweekly schedules. Cancer Research. 65. 936–936. 2 indexed citations

18.

Azria, D., Christel Larbouret, Bruno Robert, et al.. (2003). [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].. PubMed. 90 Spec No. S202–12. 7 indexed citations

19.

Culine, Stéphane, Marie-Françoise Rousseau-Merck, Nicole Honoré, C Nézelof, & Birgitta Olofsson. (1992). Specific expression of theras-Relatedrab3A gene in human normal and malignant neuroendocrine cells. Cancer. 70(10). 2552–2556. 5 indexed citations

20.

Ray, D. Le, et al.. (1990). The human homologue of the putative proto-oncogene Spi-1: characterization and expression in tumors.. PubMed. 5(5). 663–8. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact